复星医药的“超车”赌局

药智网
Jun 19, 2025

高效低毒TEV-56278是一款处于研发阶段的创新肿瘤免疫治疗药物,其核心技术源于梯瓦自主研发的ATTENUKINE技术平台。这一技术通过全新作用机制,有望实现高效低毒的治疗效果。传统高剂量IL-2疗法虽对部分晚期肾癌和黑色素瘤有效,但其严重的血管渗漏综合征、低血压等毒性反应限制了临床应用。TEV-56278是一种抗PD-1抗体-细胞因子融合蛋白,通过ATTENUKINE技术平台,选择性地将减毒的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10